Pharma Titan Joins Predicta Board, Validating a New Diagnostic Era

CAMBRIDGE, Mass. – May 20, 2026

In a move that reverberates with strategic significance for the future of cancer diagnostics, Predicta Biosciences today announced the appointment of Dr. Craig L. Tendler, a pharmaceutical industry heavyweight, to its Board of Directors. Dr. Tendler, who most recently served as a key oncology executive at Johnson & Johnson’s Janssen, brings a formidable track record that includes leadership roles in over 30 major drug approvals and 13 FDA Breakthrough Therapy designations.

This appointment is far more than a routine addition to a corporate board. It represents a powerful endorsement of Predicta's cutting-edge diagnostic technology and a calculated step to accelerate its path from the laboratory to widespread clinical adoption. For a venture-backed startup aiming to disrupt the decades-old standards of care in blood cancer, securing a director with Dr. Tendler's regulatory and commercialization prowess is a landmark achievement.

"We are honored to welcome Dr. Tendler to Predicta's Board," said Brian McKernan, CEO of Predicta Biosciences, in a statement. "Craig's perspective will be invaluable as Predicta continues to advance innovations that help ensure more patients have access to lifesaving diagnostics."

A Strategic Play for Market Acceleration

Dr. Tendler’s career is a highlight reel of modern oncology drug development. During his tenure at Janssen, he was instrumental in the global success of transformative therapies for hematologic malignancies, including the blockbuster treatments DARZALEX, IMBRUVICA, and the CAR-T therapy CARVYKTI—all cornerstones in the treatment of multiple myeloma and other blood cancers. This deep, domain-specific experience on the therapeutic side makes him uniquely qualified to guide a company developing the next generation of diagnostics for those very same diseases.

His expertise lies not just in clinical trials, but in the crucial integration of biomarkers and diagnostics into the development process—a skill set that aligns perfectly with Predicta's mission. The company, which has already launched its first diagnostic platform, GenoPredicta, is built on the premise that deeper, more sensitive molecular insights can fundamentally change treatment decisions.

"I am delighted to be joining Predicta's world-class team of clinical, genomic, and bioinformatic leaders," Dr. Tendler stated. "I look forward to integrating these important platforms across drug development programs in heme malignancies to increase the probability of success and improve outcomes for patients." His comment underscores a key strategic goal: embedding Predicta's technology within the pharmaceutical pipeline itself, making it an indispensable tool for developing new cancer drugs.

This high-profile appointment comes on the heels of significant financial momentum. After a $5.2 million seed round in 2024, Predicta secured an oversubscribed $23.4 million Series A in late 2025, with backing from prominent investors like The Engine Ventures, Illumina Ventures, and the venture arms of Mass General Brigham and Dana-Farber Cancer Institute. Adding Dr. Tendler's strategic guidance to this strong capital foundation signals that Predicta is aggressively shifting gears from research and development to full-scale commercialization and regulatory engagement.

Beyond the Biopsy: Revolutionizing Blood Cancer Care

At the heart of Predicta's value proposition is a technology that promises to replace one of the most dreaded procedures in oncology: the bone marrow biopsy. For patients with hematological malignancies like multiple myeloma, this invasive and painful procedure is a routine part of diagnosis and monitoring. However, biopsies provide only a small, localized sample of the bone marrow, often failing to capture the full genetic complexity and spatial heterogeneity of the cancer.

Predicta, founded by world-renowned scientists from the Dana-Farber Cancer Institute and the Broad Institute, has pioneered a method to overcome this limitation. Using a single blood draw, its platforms can isolate and analyze whole tumor cells circulating in the bloodstream. This liquid biopsy approach provides a comprehensive, whole-genome view of the cancer, offering unprecedented insights.

The company’s first platform, GenoPredicta, launched as a Laboratory Developed Test (LDT) in April 2025. It uses whole-genome sequencing to identify genomic alterations that can inform diagnosis, risk stratification, and targeted therapy selection. Its second platform, ImmunoPredicta, slated for a 2026 launch, will characterize the patient's immune system, providing critical data to predict response to immunotherapies like CAR T-cells and bispecific antibodies.

Perhaps most critically, the technology offers ultra-sensitive detection of Measurable Residual Disease (MRD)—the lingering cancer cells that remain after treatment and often lead to relapse. By tracking these rare cells and their clonal evolution, clinicians can potentially detect emerging drug resistance long before it becomes clinically apparent, allowing for proactive adjustments to a patient's treatment plan.

The Migration of Expertise from Pharma to Biotech

Dr. Tendler's move from a pharmaceutical giant to a nimble diagnostics startup is emblematic of a larger industry trend. Seasoned executives with decades of experience navigating the complex machinery of Big Pharma are increasingly drawn to the agility and disruptive potential of the biotech sector. This migration of talent is fueling an innovation boom, particularly at the intersection of therapeutics and diagnostics.

These leaders bring not only scientific and clinical knowledge but also an invaluable understanding of the regulatory pathways, reimbursement landscapes, and partnership ecosystems necessary to turn a promising technology into a commercially successful product. Before his transformative work at Janssen, Dr. Tendler held a senior role at Schering-Plough Research Institute, giving him a panoramic view of the industry's evolution over nearly three decades.

For companies like Predicta, which are pioneering personalized medicine, this fusion of expertise is essential. The future of cancer care depends on the seamless integration of advanced diagnostics that guide the use of powerful, targeted therapies. Dr. Tendler's career has been dedicated to developing the latter; his new role will focus on empowering the former.

With a board now fortified by one of the industry's most respected drug developers, Predicta Biosciences is poised to accelerate its mission. The combination of its foundational science, robust funding, and elite strategic leadership places the company at the vanguard of a movement set to redefine how blood cancers are diagnosed, monitored, and ultimately treated.